Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1361-1369

  Yokoyama, Yoshihito ^a,b   Stephen Charnock Jones, D ^a   Licence, Diana ^a   Yanaihara, Atsushi ^a   Hastings, Julie M ^a   Holland, Cathrine M ^a   Emoto, Makoto ^a   Sakamoto, Akiko ^b   Sakamoto, Tomomi ^b   Maruyama, Hidetoshi ^b   Sato, Shigemi ^b   Mizunuma, Hideki ^b   Smith, Stephen K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RISK; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 0037390198     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Morrow, C. P., Bundy, B. N., Kurman, R. J., Creasman, W. T., Heller, P., Homesley, H. D., and Graham, J. E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol., 40: 55-65, 1991.
2. Yokoyama, Y., Sagara, M., Sato, S., and Saito, Y. Value of glutathione S-transferase π and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas. Gynecol. Oncol., 68: 280-287, 1998.
3. Creasman, W. T. New gynecologic cancer staging. Obstet. Gynecol., 75: 287-288, 1990.
4. Calais, G., Descamps, P., Vitu, L., Body, G., Lansac, J., Bougnoux, P., and Le Floch, O. Is lymphadenectomy useful in the treatment of endometrial carcinoma?. Gynecol. Oncol., 38: 71-75, 1990.
5. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., VaSios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
6. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
7. Beck, L. J., and D'Amore, P. Vascular development: cellular and molecular regulation. FASEB J., 11: 365-373, 1997.
8. Ellis, L., and Fidler, I. Angiogenesis and metastasis. Eur. J. Cancer, 32A: 2451-2460, 1996.
9. Nicosia, R. F. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am. J. Pathol., 153: 11-16, 1998.
10. Orlandini, M., Marconcini, L., Ferruzzi, R., and Oliviero, S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. USA, 93: 11675-11680, 1996.
11. Achen, M. G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A. F., Alitalo, K., and Stacker, S. A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA, 95: 548-553, 1998.
12. Baldwin, M. E., Catimel, B., Nice, E. C., Roufail, S., Hall, N. E., Stenvers, K. L., Karkkainen, M. J., Alitalo, K., Stacker, S. A., and Achen, M. G. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. J. Biol. Chem., 276: 19166-19171, 2001.
13. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., and Alitalo, K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J., 15: 290-298, 1996.
14. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
15. Kaipainen, A., Korhonen, J., Mustonen, T., van Hinsbergh, V. W., Fang, G. H., Dumont, D., Breitman, M., and Alitalo, K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA, 92: 3566-3570, 1995.
16. Jussila, L., Valtola, R., Partanen, T. A., Salven, P., Heikkila, P., Matikainen, M. T., Renkonen, R., Kaipainen, A., Detmar, M., Tschachler, E., Alitalo, R., and Alitalo, K. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res., 58: 1599-1604, 1998.
17. Stacker, S. A., Caesar, C., Baldwin, M. E., Thornton, G. E., Williams, R. A., Prevo, R., Jackson, D. G., Nishikawa, S., Kubo, H., and Achen, M. G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med., 7: 186-191, 2001.
18. Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Jane, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., and Detmar, M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med., 7: 192-198, 2001.
19. Mandriota, S. J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D. G., Orci, L., Alitalo, K., Christofori, G., and Pepper, M. S. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J., 20: 672-682, 2001.
20. Makinen, T., Jussila, L., Veikkalo, T., Karpanen, T., Kettunen, M. I., Pulkkanen, K., Kauppinen, R., Jackson, D. G., Kubo, H., Nishikawa, S., Yla-Herttuala, S., and Alitalo, K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med., 7: 199-205, 2001.
21. Umemoto, M., Yokoyama, Y., Sato, S., Tsuchida, S., Al-Mulla, F., and Saito, Y. Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br. J. Cancer, 85: 1032-1036, 2001.
22. Kajita, T., Ohta, Y., Kimura, K., Tamura, M., Tanaka, Y., Tsunezuka, Y., Oda, M., Sasaki, T., and Watanabe, G. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br. J. Cancer, 85: 255-260, 2001.
23. Sowter, H. M., Corps, A. N., Evans, A. L., Clark, D. E., Charnock-Jones, D. S., and Smith, S. K. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab. Investig., 77: 607-614, 1997.
24. Amioka, T., Kitadai, Y., Tanaka, S., Haruma, K., Yoshihara, M., Yasui, W., and Chayama, K. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur. J. Cancer, 38: 1413-1419, 2002.
25. Eggert, A., Ikegaki, N., Kwiatkowski, J., Zhao, H., Brodeur, G. M., and Himelstein, B. P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res., 6: 1900-1908, 2000.
26. Gunningham, S. P., Currie, M. J., Han, C., Robinson, B. A., Scott, P. A., Harris, A. L., and Fox, S. B. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin. Cancer Res., 6: 4278-4286, 2000.
27. Komuro, H., Kaneko, S., Kaneko, M., and Nakanishi, Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J. Cancer Res. Clin. Oncol., 127: 739-743, 2001.
28. Andre, T., Kotelevets, L., Vaillant, J. C., Coudray, A. M., Weber, L., Prevot, S., Parc, R., Gespach, C., and Chastre, E. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int. J. Cancer, 86: 174-181, 2000.
29. Boocock, C. A., Charnock-Jones, D. S., Sharkey, A. M., McLaren, J., Barker, P. J., Wright, K. A., Twentyman, P. R., and Smith, S. K. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J. Natl. Cancer Inst. (Bethesda), 87: 506-516, 1995.
30. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., and Senger, D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143: 1225-1262, 1993.
31. Decaussin, M., Sartelet, H., Robert, C., Moro, D., Claraz, C., Brambilla, C., and Brambilla, E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J. Pathol., 188: 369-377, 1999.
32. Ohta, Y., Shridhar, V., Bright, R. K., Kalemkerian, G. P., Du, W., Carbone, M., Watanabe, Y., and Pass, H. I. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer, 81: 54-61, 1999.
33. White, J. D., Hewett, P. W., Kosuge, D., McCulloch, T., Enholm, B. C., Carmichael, J., and Murray, J. C. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res., 62: 1669-1675, 2002.
34. George, M. L., Tutton, M. G., Janssen, F., Arnaout, A., Abulafi, A. M., Eccles, S. A., and Swift, R. I. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia, 3: 420-427, 2001.
35. Niki, T., Iba, S., Tokunou, M., Yamada, T., Matsuno, Y., and Hirohashi, S. Expression of vascular endothelial growth factor A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res., 6: 2431-2439, 2000.
36. O-charoenrat, P., Rhys-Evans, P., and Eccles, S. A. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer (Phila.), 92: 556-568, 2001.
37. Kurebayashi, J., Otsuki, T., Kunisue, H., Mikami, Y., Tanaka, K., Yamamoto, S., and Sonoo, H. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res., 90: 977-981, 1999.
38. Debinski, W., Slagle-Webb, B., Achen, M. G., Stacker, S. A., Tulchinsky, E., Gillespie, G. Y., and Gibo, D. M. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol. Med., 7: 598-608, 2001.
39. Battista, S., de Nigris, F., Fedele, M., Chiappetta, G., Scala, S., Vallone, D., Pierantoni, G. M., Mega, T., Santoro, M., Viglietto, G., Verde, P., Fusco, A., and Megar, T. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene, 17: 377-385, 1998.
40. Zoumpourlis, V., Papassava, P., Linardopoulos, S., Gillespie, D., Balmain, A., and Pintzas, A. High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene, 19: 4011-4021, 2000.
41. Yonemura, Y., Endo, Y., Fujita, H., Fushida, S., Ninomiya, I., Bandou, E., Taniguchi, K., Miwa, K., Ohoyama, S., Sugiyama, K., and Sasaki, T. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res., 5: 1823-1829, 1999.
42. Jacquemier, J., Mathoulin-Portier, M. P., Valtola, R., Charafe-Jauffret, E., Geneix, J., Houvenaeghel, G., Puig, B., Bardou, V. J., Hassoun, J., Viens, P., and Birnbaum, D. Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3. Int. J. Cancer, 89: 69-73, 2000.
43. Moriyama, M., Kumagai, S., Kawashiri, S., Kojima, K., Kakihara, K., and Yamamoto, E. Immunohistochemical study of tumor angiogenesis in oral squamous cell carcinoma. Oral Oncol., 33: 369-374, 1997.